What question did this study set out to answer?

This study evaluates treatment outcomes and patterns between neoadjuvant chemotherapy and endocrine therapy in ER+/HER2− and HER2-low early breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS3-09-30: Real-World Outcomes of Neoadjuvant Chemotherapy vs Endocrine Therapy in ER+/HER2− and HER2-Low Early Breast Cancer: A Single-Institution Retrospective Study

View Full Paper

Ask AI

Bookmark

This study evaluates treatment outcomes and patterns between neoadjuvant chemotherapy and endocrine therapy in ER+/HER2− and HER2-low early breast cancer.
Retrospective analysis of 211 ER+/HER2− or HER2-low early breast cancer patients
Comparison of neoadjuvant chemotherapy (n=169) and endocrine therapy (n=42)
Assessment of pathological complete response, nodal and tumor downstaging, and recurrence-free survival
9.5% of NAC patients achieved pathological complete response vs. 4.8% in NET group
Nodal downstaging observed in 16.6% of NAC vs. 7.1% of NET patients
Tumor downstaging in 68.3% of NAC vs. 74.2% of NET surgery patients
Breast-conserving surgery achieved in 17.8% of NAC vs. 9.5% of NET patients
Distant recurrence rates were 6.5% for NAC and 2.4% for NET, with median RFS of 20.6 months for NAC and 13.3 months for NET

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

A retrospective study compares outcomes of neoadjuvant chemotherapy and endocrine therapy in early breast cancer, indicating distinct clinical populations.

Cite This Study

ALMAZYAD et al. (2026) studied this question.

synapsesocial.com/papers/6996a8c7ecb39a600b3efd2c https://doi.org/10.1158/1557-3265.sabcs25-ps3-09-30

View Full Paper

Ask AI

Bookmark

Implication

A retrospective study compares outcomes of neoadjuvant chemotherapy and endocrine therapy in early breast cancer, indicating distinct clinical populations.

Abstract PS3-09-30: Real-World Outcomes of Neoadjuvant Chemotherapy vs Endocrine Therapy in ER+/HER2− and HER2-Low Early Breast Cancer: A Single-Institution Retrospective Study

Key Points

Discussion

Implication

Cite This Study

Abstract PS3-09-30: Real-World Outcomes of Neoadjuvant Chemotherapy vs Endocrine Therapy in ER+/HER2− and HER2-Low Early Breast Cancer: A Single-Institution Retrospective Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider